ArticleCancers2022

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.

Hossein Taghizadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.